Sedana Medical AB (publ) (SEDANA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's Finwire broadcast presentation with Sedana Medical. After the presentation, there will be a question and answer session. So if you have any questions, you can submit them using the form on the right. In case you are following the report with the phone, you can push star 9 on your telephone keypad to raise your hand and star 6 to lower the hand. With that said, I'll hand the floor to you. Please go ahead. Thank you for the introduction and a warm welcome to our Q4 and full year report 2025. This report stands out for me in a very positive way because we delivered on an ambitious goal that we set for ourselves. Coming out of the COVID-19 pandemic and being faced with a sharp revenue decline and the biggest loss in Sedana's medical history in 2022, we committed to the goal to reach profitability in our core business before we launched inhaled sedation in the US. because we believed that it was essential to build our U.S. expansion on a stable cash generating platform to demonstrate proof of concept, but also to help finance the launch investments in the U.S. Now, a few years later, I'm proud to say that we have delivered on that ambition and we have reached a positive EBITDA in our ex-U.S. business for the full year 2025. This is the first time for Sedana Medical in its history as a listed company. So let's jump into the slides on page three, which shows our progress in our three priority areas, sales, growth, profitability, and the US. On the sales side, we've ended the year at 200 million SEK, which represents a year-over-year growth of 16%, excluding exchange rate effects. 12% out of these 16 was organic, and the remaining 4% stem from our contract manufacturing business in Malaysia. This marks an all-time high in sales for the full year,...